Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...

GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...

Contrast agents could provide an efficient means for physicians to detect infections through imaging, rather than unnecessarily prescribing antibiotics, according to a Technology Review report. Two ...

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...

Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

CHICAGO--(BUSINESS WIRE)--Ultrasound contrast agents show promise for detecting and evaluating uterine disorders and prostate cancers, scientists reported today at the annual Advances in Contrast ...

Nanomedicine. 2015;10(2):321-341. Delivery: "Go where we want." The contrast agent must be able to be delivered in vivo and transported to the site of interest. Nontoxic: "Do no harm along the way." ...